{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:47:35Z","timestamp":1794944855366,"version":"4.9.1"},"reference-count":115,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Differentiation syndrome (DS) is a frequent and potentially life-threatening clinical syndrome first recognized with the advent of targeted therapeutics for acute promyelocytic leukemia (APL). DS was subsequently observed more broadly with targeted therapeutics for acute myeloid leukemia (AML). DS is typically characterized by fever, dyspnea, hypotension, weight gain, pleural or pericardial effusions, and acute renal failure. The incidence in patients with APL ranges from 2 to 37%, with the wide variation likely attributed to different diagnostic criteria, use of prophylactic treatment, and different treatment regimens. Treatment with corticosteroids +\/- cytoreductive therapy should commence as soon as DS is suspected to reduce DS-related morbidity and mortality. The targeted anti-leukemic therapy should be discontinued in patients with severe DS. Here, we discuss the pathogenesis of DS, clinical presentations, diagnostic criteria, management strategies, and implementation of prospective tracking on clinical trials.<\/jats:p>","DOI":"10.3390\/cancers15194767","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:50:26Z","timestamp":1695887426000},"page":"4767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Differentiation Syndrome in Acute Leukemia: APL and Beyond"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4878-5463","authenticated-orcid":false,"given":"Ashley C.","family":"Woods","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Norsworthy","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.18632\/oncotarget.27513","article-title":"Acute promyelocytic leukemia (APL): A review of the literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","article-title":"Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML","volume":"66","author":"Kakizuka","year":"1991","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/asheducation-2008.1.391","article-title":"Curative strategies in acute promyelocytic leukemia","volume":"2008","author":"Tallman","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","article-title":"Acute promyelocytic leukemia: Results of treatment by daunorubicin","volume":"41","author":"Bernard","year":"1973","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial","volume":"2","author":"Iland","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.V128.22.896.896","article-title":"ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG\/Alliance\/ECOG S0535 Trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia","volume":"369","author":"Avvisati","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V92.8.2712","article-title":"Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group","volume":"92","author":"Dombret","year":"1998","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gasparovic, L., Weiler, S., Higi, L., and Burden, A.M. (2020). Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103342"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"ref_16","first-page":"1014","article-title":"Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell\u2019Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups","volume":"90","author":"Mandelli","year":"1997","journal-title":"Blood"},{"key":"ref_17","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome","volume":"95","author":"Tallman","year":"2000","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_22","unstructured":"(2023, August 17). FDA Warns That Symptoms of a Serious Condition Affecting the Blood Cells Are Not Being Recognized with the Leukemia Medicine Idhifa (Enasidenib). Press Release, Available online: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-warns-symptoms-serious-condition-affecting-blood-cells-are-not-being-recognized-leukemia."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1062524","DOI":"10.3389\/fonc.2022.1062524","article-title":"The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions","volume":"12","author":"Iyer","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.leu.2403284","article-title":"Retinoic acid syndrome in NOD\/scid mice induced by injecting an acute promyelocytic leukemia cell line","volume":"18","author":"Ninomiya","year":"2004","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.leukres.2005.01.005","article-title":"Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells","volume":"29","author":"Shibakura","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.1999.01671.x","article-title":"All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow","volume":"107","author":"Brown","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.V90.7.2747","article-title":"Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2","volume":"90","author":"Larson","year":"1997","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<72::AID-IJC11>3.0.CO;2-F","article-title":"Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells","volume":"70","author":"Taraboletti","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2141.1996.4911029.x","article-title":"All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4","volume":"93","author":"Marchetti","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1164\/ajrccm.158.4.9709085","article-title":"Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome","volume":"158","author":"Nicolls","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.10156","article-title":"ATRA syndrome with extensive organ infiltration","volume":"71","author":"Kakkar","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2011059","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: Experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_34","first-page":"1","article-title":"Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: A variant form of the differentiation syndrome?","volume":"58","author":"Vassilakopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/ijmpo.ijmpo_36_16","article-title":"Pancreatitis in Acute Promyelocytic Leukemia: Drug-induced or Differentiation Syndrome?","volume":"38","author":"De","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3341\/kjo.2020.0101","article-title":"Ocular Symptom Can Be the First Presentation of Differentiation Syndrome in Acute Promyelocytic Leukemia","volume":"35","author":"Gim","year":"2021","journal-title":"Korean J. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajoc.2018.01.026","article-title":"Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide","volume":"9","author":"Newman","year":"2018","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.18240\/ijo.2021.02.22","article-title":"Exudative hemorrhagic retinopathy related to all-trans retinoic acid differentiation syndrome in a patient with acute promyelocytic leukemia","volume":"14","author":"Tam","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2147\/JPR.S305192","article-title":"Differentiation Syndrome with Severe Abdominal Pain During Induction Treatment of Acute Promyelocytic Leukemia: A Case Report","volume":"14","author":"Yan","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_40","first-page":"e24213","article-title":"A Rare Case of Acute Pericarditis as a Primary Presentation of Differentiation Syndrome","volume":"14","author":"Alyami","year":"2022","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4250\/jcu.2011.19.2.95","article-title":"Reversible Symptomatic Myocarditis Induced by All-Trans Retinoic Acid Administration during Induction Treatment of Acute Promyelocytic Leukemia: Rare Cardiac Manifestation as a Retinoic Acid Syndrome","volume":"19","author":"Choi","year":"2011","journal-title":"J. Cardiovasc. Ultrasound"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-021-00124-9","article-title":"Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: A case report","volume":"7","author":"Shenoy","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ICB.0b013e3182618d6c","article-title":"All-trans retinoic Acid differentiation syndrome chorioretinopathy: A case of multifocal serous neurosensory detachments in a patient with acute promyelocytic leukemia treated with all-trans retinoic Acid","volume":"7","author":"Levasseur","year":"2013","journal-title":"Retin Cases Brief Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V88.4.1390.bloodjournal8841390","article-title":"AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) pilot study","volume":"88","author":"Avvisati","year":"1996","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1038\/s41598-019-47937-4","article-title":"Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia","volume":"9","author":"Yoon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4329\/wjr.v6.i8.583","article-title":"Pathophysiology, clinical features and radiological findings of differentiation syndrome\/all-trans-retinoic acid syndrome","volume":"6","author":"Cardinale","year":"2014","journal-title":"World J. Radiol."},{"key":"ref_48","first-page":"326","article-title":"S\u00edndrome de diferenciaci\u00f3n en paciente con leucemia promieloc\u00edtica aguda: Importancia de la TC de t\u00f3rax","volume":"56","year":"2019","journal-title":"Arch. Bronconeumol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841859709172077","article-title":"Retinoic acid syndrome\u2014Radiological features","volume":"38","author":"Islam","year":"1997","journal-title":"Acta Radiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2214\/ajr.178.2.1780475","article-title":"Radiologic features of all-trans-retinoic acid syndrome","volume":"178","author":"Jung","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428199609054809","article-title":"Retinoic acid syndrome: Pulmonary computed tomography (CT) findings","volume":"23","author":"Davis","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15153","article-title":"Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia","volume":"184","author":"Karunakaran","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_53","first-page":"774","article-title":"Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group","volume":"9","author":"Wiley","year":"1995","journal-title":"Leukemia"},{"key":"ref_54","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA group","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome","volume":"115","author":"Sanz","year":"2010","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2003","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MOH.0000000000000215","article-title":"Optimal treatment strategies for high-risk acute promyelocytic leukemia","volume":"23","author":"Norsworthy","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia","volume":"8","author":"Kutny","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zou, Y., Chen, Y., Guo, Y., Yang, W., Chen, X., Wang, S., Liu, X., Ruan, M., and Zhang, J. (2018). Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: A randomized controlled trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4280-2"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2018-03-836528","article-title":"Risk-adapted treatment of acute promyelocytic leukemia: Results from the International Consortium for Childhood APL","volume":"132","author":"Testi","year":"2018","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/102453312X13451850327262","article-title":"Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia","volume":"17","author":"Pei","year":"2012","journal-title":"Hematology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group","volume":"112","author":"Sanz","year":"2008","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"Montesinos","year":"2008","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.HS9.0000844852.66856.8e","article-title":"P491: Predictive factors of differentiation syndrome in patients with acute promyelocytic leukemia","volume":"6","author":"Bchir","year":"2022","journal-title":"HemaSphere"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"Ehninger","year":"2015","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"ref_72","first-page":"2019-vol4","article-title":"Acute kidney failure in differentiation syndrome: A possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report","volume":"36","author":"Mirenghi","year":"2019","journal-title":"G. Ital. Nefrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_74","unstructured":"Servier Laboratories (2022). TIBSOVO\u00ae (Ivosidenib) Prescribing Information, Servier Laboratories."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_77","unstructured":"Bristol Myers Squibb (2017). IDHIFA\u00ae(Enasidenib) Prescribing Information, Bristol Myers Squibb. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209606s000lbl.pdf."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","article-title":"Olutasidenib: From bench to bedside","volume":"7","author":"Venugopal","year":"2023","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_80","unstructured":"Rigel Pharmaceuticals, Inc (2022). REZLIDHIA\u2122 (Olutasidenib) Prescribing Information, Rigel Pharmaceuticals, Inc.. Available online: https:\/\/www.rezlidhia.com\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_85","unstructured":"Astellas Pharma, Inc (2019). XOSPATA\u00ae (Gilteritinib) Prescribining Information, Astellas Pharma, Inc.. Available online: https:\/\/astellas.us\/docs\/xospata.pdf."},{"key":"ref_86","unstructured":"Daichii Sankyo Basking (2023). VANFLYTA\u00ae(Quizartinib) Prescribing Information, Daichii Sankyo Basking. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216993s000lbl.pdf."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_91","first-page":"1422","article-title":"Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone","volume":"30","author":"Canaani","year":"2015","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e243615","DOI":"10.1136\/bcr-2021-243615","article-title":"Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML","volume":"14","author":"Alkassis","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_93","first-page":"1099005","article-title":"A Rare Case of Midostaurin-Associated Sweet\u2019s Syndrome","volume":"2022","author":"Yasin","year":"2022","journal-title":"Case Rep. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2013-01-478172","article-title":"FLT3 inhibitor-induced neutrophilic dermatosis","volume":"122","author":"Fathi","year":"2013","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamadermatol.2015.6121","article-title":"FLT3Inhibitor\u2013Associated Neutrophilic Dermatoses","volume":"152","author":"Varadarajan","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"A877","DOI":"10.1016\/j.chest.2021.07.820","article-title":"Differentiation syndrome after gilteritinib: A tricky mimicker of sepsis","volume":"160","author":"Dugan","year":"2021","journal-title":"Chest"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Khaled","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2217\/fon-2017-0160","article-title":"Midostaurin for the treatment of acute myeloid leukemia","volume":"13","author":"Patnaik","year":"2017","journal-title":"Future Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: Latest updates from 2022 ASH Annual Meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_105","unstructured":"Kura Oncology Press (2021). Kura Oncology Provides Update on Phase 1b Study of ko-539 in Acute Myeloid Leukemia, Kura Oncology Press. Available online: https:\/\/bit.ly\/3HJKG4N."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.ccm.0000907164.42526.85","article-title":"359: Fatal differentiation syndrome secondary to menin inhibitors: A case series","volume":"51","author":"Hanmandlu","year":"2023","journal-title":"Crit. Care Med."},{"key":"ref_107","unstructured":"Kura Oncology Press (2022). Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of Ko-539 in Acute Myeloid Leukemia, Kura Oncology Press. Available online: https:\/\/bit.ly\/3qWSzNP."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e2011061","DOI":"10.4084\/mjhid.2011.061","article-title":"Pseudo differentiation syndrome","volume":"3","author":"Khalaf","year":"2011","journal-title":"Mediterr J. Hematol. Infect Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/blood.V104.11.4528.4528","article-title":"Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.12598","article-title":"Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine","volume":"95","author":"Laufer","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_111","unstructured":"Otsuka Pharmaceuticals Co., Ltd. (2023, August 17). DACOGEN\u00ae (Decitabine) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021790s021lbl.pdf."},{"key":"ref_112","unstructured":"(2023, August 17). Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed\/Refractory AML\/MDS. Press Release. Available online: https:\/\/ir.foghorntx.com\/news-releases\/news-release-details\/foghorn-therapeutics-provides-further-update-fhd-286-phase-i\/."},{"key":"ref_113","unstructured":"(2023, June 05). Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and\/or Refractory AML\/MDS Patients. Press Release. Available online: https:\/\/ir.foghorntx.com\/news-releases\/news-release-details\/foghorn-therapeutics-announces-fda-has-lifted-clinical-hold."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2017.09.001","article-title":"The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia","volume":"32","author":"Jillella","year":"2018","journal-title":"Blood Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:26Z","timestamp":1760130026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":115,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194767"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194767","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}